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Abstract: N-Acetylglucosamine (GlcNAc) is a monosaccharide that usually polymerizes 
linearly through (1,4)-β-linkages. GlcNAc is the monomeric unit of the polymer chitin, the 
second most abundant carbohydrate after cellulose. In addition to serving as a component 
of this homogeneous polysaccharide, GlcNAc is also a basic component of hyaluronic acid 
and keratin sulfate on the cell surface. In this review, we discuss the industrial production 
of  GlcNAc,  using  chitin  as  a  substrate,  by  chemical,  enzymatic  and  biotransformation 
methods. Also, newly developed methods to obtain GlcNAc using glucose as a substrate in 
genetically  modified  microorganisms  are  introduced.  Moreover,  GlcNAc  has  generated 
interest not only as an underutilized resource but also as a new functional material with 
high potential in various fields. Here we also take a closer look at the current applications 
of  GlcNAc,  and  several  new  and  cutting  edge  approaches  in  this  fascinating  area  are 
thoroughly discussed. 
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1. Introduction  
Carbohydrates, with the general formula Cm(H2O)n, are the most abundant organic compounds in 
living organisms. Also known as saccharides, carbohydrates are involved in a variety of biological 
events. Fox example, they serve as the main source and storage form of energy as well as structural 
components. Monosaccharides, the monomers of carbohydrates, serve as the main source of energy for 
metabolism  (e.g.,  glucose)  and  are  used  in  biosynthesis  [1].  Their  derivatives  are  also  important 
components of coenzymes and the backbone of genetic molecules. Furthermore, carbohydrates are 
essential in cell interactions [2], signal transduction [3,4], antibody recognition [5], tumor metastasis 
[6], hormones [7] and musculoskeletal physiology [8,9].  
N-Acetylglucosamine (GlcNAc), 2-acetamino-2-deoxy-β-D-glucose or 2-(acetylamino)-2-deoxy-D-
glucose, is a monosaccharide derivative of glucose and is widely distributed worldwide. The molecular 
formula of this amino monosaccharide is C8H15NO6, and its molecular weight is 221.21. In general, it 
is a white and slightly sweet powder that melts at 221 °C . The solubility of GlcNAc is 25% in water, 
and 1% aqueous solutions are colorless and clear.  
GlcNAc polymerizes linearly with (1,4)-β-linkages and is the monomeric unit of the polymer chitin, 
the second most abundant carbohydrate after cellulose. Chitin is present in arachnids, most fungal cell 
walls, insect exoskeletons, the shells of crustaceans and parts of invertebrates [10,11]. It is also present 
as an extracellular polymer of some microbes [12,13]. Isolated chitin exists as two allomorphs, namely 
α-chitin and β-chitin. α-chitin is the most abundant by far and is present in shrimp and crab shells. The 
rarer β-chitin is found in squid pens and is commercially more expensive. To date, it is not possible to 
obtain β-chitin either from solution or by in vitro biosynthesis. 
In addition to being a structural component of homogeneous polysaccharides like chitin, GlcNAc is 
also a constituent of heterogeneous polysaccharides, such as murein [10–14] and hyaluronic acid (also 
called hyaluronan or hyaluronate, HA) [14]. Murein is the basic component of the bacterial cell wall 
and consists of crosslinked peptide chains with repeating GlcNAc and muramic acid residues [14]. HA 
is a linear heteropolysaccharide that is composed of repeating D-glucuronic acid and GlcNAc residues 
[14]. As early as 1943, HA was discovered in bovine eyes, and its defect causes disease. In fact, it is 
the major component of the extracellular matrix and is extensively distributed in connective, epithelial 
and neural tissues [15–20]. HA performs numerous roles in cell motility, inflammation and cancer 
metastasis [21]. In addition to its contributions in eukaryotes, HA is also a component of cell coatings 
in some bacteria [22]. HA can be produced by biochemical engineering techniques [23,24]. 
Chondroitin is a glycosaminoglycan that is composed of the same repeats as HA but is sulfated at 
position C-4 or C-6 of the N-acetylgalactosamine residues. It is also plentiful in connective tissues, 
particularly in blood vessels, bone and cartilage. In fact, GlcNAc and sulfated GlcNAc can be isolated 
from  heparin  or  keratin  sulfate  [25,26].  Heparin,  which  is  produced  by  basophils  and  mast  cells, 
consists of a variably-sulfated repeating disaccharide unit and acts as an anticoagulant. The major 
repeating disaccharide unit of keratin sulfate, also called keratosulfate, is composed of galactose and 
sulfated GlcNAc. Keratin sulfate is distributed in the cornea, cartilage and bone and usually acts as a 
cushion in joints to absorb mechanical shock. 
Moreover, GlcNAc molecules with various functional group substitutions serve as ingredients of 
cell surface decoration and/or are directly involved in cell interactions [5]. Indeed, these carbohydrates Mar. Drugs 2010, 8                       
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may  increase  the  specificity  and  interaction  force  between  cells.  For  example,  blood  type  usually 
depends on the oligosaccharides present of the surface of erythrocytes in human beings, and GlcNAc 
appears  to  be  the  basic  element  of  the  H  antigen  in  ABO  blood  grouping  [5].  GlcNAc  was  also 
identified in the two epitopes Sialy-Lewis X and Sialy-Lewis A. They are ligands that capture selectins 
for adhesion, but they also contribute significantly to metastasis [6,27–29].  
In addition,  glycoproteins  that contain GlcNAc can be found in  the mucous membranes of the 
digestive  tract.  However,  saccharide  modification  may  promote  pathogen  binding.  For  example, 
GlcNAc-β-(1-4)-GlcNAc  is  present  in  membrane  proteins  of  brain  microvascular  endothelial  cells 
(BMECs) and acts as the ligand for Escherichia coli K1 outer membrane protein A (OmpA) to mediate 
bacterial transport through the blood-brain barrier in neonates [30,31].  
Generally,  oligosaccharide  modification  is  proposed  to  play  a  role  in  structural  stability  and 
interaction  with  other  molecules.  In  particular,  O-GlcNAcylation  affects  performance,  including 
activity, stability and/or localization [32]. O-linked GlcNAc usually modifies nuclear pore proteins that 
are involved in nuclear pore assembly and function [33]. However, N-GlcNAcylated glycoproteins are 
cleared more rapidly by lysosomal glycosidases [34].  
In plants, GlcNAc has been found in bromelain, ricin agglutinin and abrus agglutinin [7,35–37]. In 
humans, GlcNAc is frequently observed in glycoproteins, such as tissue plasminogen activator [38]. It 
is  also  detected  in  mammalian  growth  factors  and  hormones  [35],  including  follicle-stimulating 
hormone (FSH), luteinizing hormone (LH), human menopausal gonadotropin (hMP), pregnant mare 
serum gonadotropin, thyroid-stimulation hormone (TSH) and human chorionic gonadotropin (hCG). 
Recently,  GlcNAc  and  its  derivates  been  utilized  in  dietary  supplements  and  for  therapeutic 
development [8,39–41] due to its unique characteristics. Toxicity tests reveal that GlcNAc is non-toxic, 
supporting the essential safety issue, and the half-life of GlcNAc with 20 g intravenous injection is  
220  min  [42].  While  800  mg  administrated  per  os,  the  mean  maximum  concentration  (Cmax)  of 
GlcNAc in plasma was 162.7 ±  125.2 ng/mL and the time for maximum concentration (Tmax) was  
1.56 ±  1.23 h [43]. It was further demonstrated that 54% of the administered glucosamine (GlcN) was 
excreted  into  the  urine  in  one  day,  indicating  the  clearance  pathway  of  GlcNAc  [42].  Therefore, 
GlcNAc can potentially be utilized in many significant applications. 
2. Production of N-Acetyl-D-glucosamine 
In  mammals,  GlcNAc  and  GlcN  are  components  of  glycoproteins,  proteoglycans, 
glycosaminoglycans  (GAGs) and other connective tissue building blocks [15–20]. Despite being a 
building block of biomacromolecules, GlcNAc seldom exists in free form, except in human milk (at 
600–1500  mg/mL)  [44,45].  Because  GlcNAc  not  only  play  a  role  in  plant  organogenesis  and 
invertebrate embryogenesis [46] but also has therapeutic potential in the treatment of a wide variety of 
diseases,  economic  feed-stocks  and  high  efficiency  processes  for  producing  GlcNAc  are  urgently 
needed in industry. Every year, about 100 billion tons of chitin are produced in nature [47–49], making 
chitin a suitable biomass resource for the production of GlcNAc. Using chitin as feed-stock, GlcNAc 
can be prepared through a process that is based on chitin hydrolysis. Figure 1 summarizes the processes 
of GlcNAc production to date. Mar. Drugs 2010, 8                       
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2.1. Chemical methods to produce GlcNAc 
GlcNAc has historically been commercially prepared by several companies via a process based on 
the acid hydrolysis of crude chitin. Generally, the chemical degradation of chitin can be performed 
through hydrolysis using a strong acid, such as HCl. The processing temperature and concentration of 
the acid should be carefully selected. These parameters must be high enough to sufficiently degrade 
chitin  but  not  so  high  that  the  GlcNAc  product  is  destroyed.  Suitable reaction conditions  include  
15–36% HCl and about 40–80 ° C. In this procedure, up to 6.42 g/L GlcNAc can be produced in 1 h 
[50]. However, there appears to be several problems in producing GlcNAc by the direct acid hydrolysis 
of chitin, including high cost, low yield (below 65%) and acidic waste created by the use of HCl [51]. 
An alternative process involves the use of GlcN. Chitin can be dissolved in concentrated HCl and 
heated in boiling water for 3 h. In such drastic conditions, the acetyl group of GlcNAc is removed. An 
additional N-acetylation reaction must then be performed to produce GlcNAc. In a typical preparation, 
GlcN  is  dissolved  in  10%  methanol  and  is  N-acetylated  with  acetic  anhydride  in  the  presence  of  
Dowex 1 (carbonate form). After filtration and crystallization, this process can generate an overall 
yield  of  43%  GlcNAc [52,53]. Another improved  N-acetylation  procedure was  described by Zhan 
(2007). GlcN is N-acetylated using pyridine as a solvent in the presence of tributylamine and acetic 
anhydride. After a series of purification procedures, ~99% pure GlcNAc can be obtained. The yield of 
this method has been reported to be higher than 70% [54]. 
Although the production of GlcNAc by chemical methods is estimated to be sufficiently economic, 
the product is not considered a natural material due to its chemical modification [51]. In addition to  
N-acetylated  products,  trace  amounts  of  O-acetylated  and  di-acetylated  products  have  also  been 
detected by LC-MS. Furthermore, solvent and tributylamine are present in the product, as determined 
by GC-MS (unpublished data). Thus, chemically produced GlcNAc usually tastes bitter due to these 
residual substances. 
Several efforts have been made to improve the purity of GlcNAc produced by chemical methods. 
Ryosuke  et  al.  (2000)  combined  the  acid  hydrolysis  of  chitin  and  ion-exchange  membrane 
electrophoresis  to  prepare  natural  GlcNAc  [55].  Zhan  (2007)  established  a  novel  purification  and 
recrystallization  procedure  to  prepare  GlcNAc  with  purity  that  was  higher  than  99.95%  [54].  In 
addition, the ozone treatment has been developed [56]. Thus, it will be possible to use chemically 
modified  GlcNAc as  an inexpensive resource in  food additives, cosmetics  and pharmaceuticals  in  
the future. 
2.2. Enzymatic methods to produce GlcNAc 
GlcNAc produced by chemical methods is not widely commercialized, not only due to technical 
reasons but also because of environment concerns. The large quantities of chemical waste resulting 
from chemical processes are not environmentally friendly. However, the enzymatic hydrolysis of chitin 
can produce GlcNAc under mild conditions. 
The enzymes degrading chitin, chitinases, distributes in various organisms [10]. They involves in 
the  physiological  and  pathological  functions  [57–62].  The  ensemble  of  chitinolytic  enzymes  can 
contain endochitinases (EC 3.2.1.14), exochitinases (EC 3.2.1.52), chitobiosidases (EC 3.2.1.30) and Mar. Drugs 2010, 8                       
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N-acetylglucosaminidases  (NAGases)  (EC  3.2.1.96)  that  are  produced  and  secreted  from  either  a 
prokaryotic or eukaryotic organism [10]. Usually, the endochitinases within microbes cleave chitin 
randomly at internal sites on the glycosidic bonds between GlcNAc residues, and such generates the 
soluble and low molecular weight oligosaccharides (e.g., tetramers, trimers and dimers). To increase 
the solubilization of chitin is essential as the first step. Then, the exochitinases or chitobiosidases in 
some organisms catalyze the progressive release of dimers, starting at the non-reducing end of chitin. 
Finally,  NAGases  cleave  the  oligomers  and  dimers,  which  are  produced  by  endochitinases  and 
exochitinases, to generate GlcNAc [63,64]. Several crude enzymes isolated from Trichoderma viride, 
Aspergillus niger, Carcica papaya L. and Aeromonium have been found to degrade β-chitin and to 
produce GlcNAc efficiently [51]. In contrast, some other microbes, such as Trichoderma hamatum 
AB10282 strain (FERM BP-10623) or Trichoderma harzianum AB10283 strain (FERM BP-10624), 
produce GlcNAc in the medium without the presence of chitin or chitin derivatives [65]. 
For the industrial production of GlcNAc, a large quantity of enzymes can be purified from the mass 
production of microbes or genetically engineered microorganisms [66–68]. However, owing to the low 
physiological  content of chitinase in organisms, the direct purification of chitinase, even from the 
fermentation broth of genetically engineered microbes, is expensive. Some commercial, unspecific, 
crude enzymes, such as cellulose, lysozyme, papain and lipase, also degrade chitin due to the presence 
of  endo-  and  exochitinase  in  crude  enzyme  preparations  [69–71].  These  unusual  enzymes  are 
inexpensive, and large amounts of them can be easily obtained commercially. 
Several enzymatic processes can be performed to produce GlcNAc. Sashiwa et al. (2002) described 
the  effective  production  of  GlcNAc  from  flake  type  α-chitin  by  crude  enzymes  derived  from 
Aeromonas hydrophila H2330 [72]. In this study, the selective production of GlcNAc from α-chitin 
was achieved with a yield up to 77% in 10 days. Although high yield and purity was achieved, low 
productivity  was  the  crucial  defect  of  this  method.  Another  process  has  been  described  by 
Pichyangkura et al. (2002) in which crude chitinases from Bacillus licheniformis SK-1 were used to 
digest α-chitin powder for the production of GlcNAc. However, only a 41% yield of GlcNAc was 
achieved along with the production of chitobiose [73]. 
Poor yields were reported in these studies using α-chitin as a substrate. The major impediment of the 
enzymatic hydrolysis process is the extremely low susceptibility of natural α-chitin due to its high 
crystallinity. In another experiment, the hydrolysis of β-chitin, which shows good swelling properties 
compared with α-chitin, was accomplished by crude enzymes (e.g., cellulose T and A), and a yield of 
nearly  100%  was  achieved  [74].  It  is  worth  noting  that the amorphous portion  of chitin  is  easily 
hydrolyzed, and the remaining tightly packed chitin is hydrolyzed slowly. 
Almost 100% pure GlcNAc was produced using crude enzymes from A. hydrophila H2330 [72], 
while chitobiose was synergistically produced using Bacillus chitinases [73]. This finding indicates that 
endochitinase, exochitinase and NAGase are necessary for the complete digestion of chitin, and higher 
NAGase activity results in a higher purity of GlcNAc. Thus, the chitin crystalline structure and the 
enzymatic composition of the reaction are two crucial factors in the production of GlcNAc through 
enzymatic methods. 
 Mar. Drugs 2010, 8                       
 
 
2498 
2.3. Improved enzymatic methods to produce GlcNAc 
The ability of chitin to act as a substrate for enzymatic hydrolysis might be improved by treatments 
that lead to its decrystallization. Several productive processes have been used to improve the purity and 
productivity  of  GlcNAc.  Most  of  these  processes  focus  on  the  modification  of  the  chitin  crystal 
structure  because  decrystallized  chitins  are  more  susceptible  to  enzymatic  hydrolysis  than  
natural chitin. 
The crystallographic parameters of chitin reveal that there are two anti-parallel molecules per unit 
cell in α-chitin, while only one is present in β-chitin. The proposed crystal structures of α-chitin and  
β-chitin are organized into sheets that are tightly held by a number of intra-sheet hydrogen bonds. In 
addition,  some  inter-sheet  hydrogen  bonds  are  also  present  in  α-chitin  but  not  in  β-chitin.  Thus,  
α-chitin is thermodynamically more stable than β-chitin [75]. When β-chitin crystals are destroyed 
during acid swelling, new crystals of α-chitin are produced during recrystallization. The crystallinity of 
different  chitin  substances  can  be  detected  by  X-ray  diffractograms  [76].  The  limited  enzymatic 
hydrolysis of natural chitin may be attributed to a limited accessibility of β-glycosidic bonds in the 
interior of the chitin crystal structure. Thus, β-chitin is degraded much more readily than α-chitin due 
to its weak intermolecular forces [77]. Sashiwa et al. (2001) obtained GlcNAc from 1% β-chitin by 
hydrolysis  with  various  commercial  enzymes,  such  as  cellulose,  hemicellulase,  papain,  lipase  and 
pectinase. The highest yield (~76%) was obtained after eight days of hydrolysis with 20 mg/mL of 
cellulose [51]. 
Heat-treating chitin in a hydrophobic solvent or surfactant is suggested to weaken the hydrogen 
bonding or hydrophobic interactions of the crystal structure and, thus, facilitate the action of enzymes 
for decomposition. Chitin colloidized is better access for enzymes digestion [78]. Kawasaki et al. 
treated chitin using straight-chain hydrocarbons, surfactants (e.g., Triton X-100 or Tween 20) and urea 
to loosen the chitin structure and then heated or ultrasonicated the mixtures. These treatments increase 
the conversion ratio of chitin [79].  
It is also possible to efficiently decompose chitin by exposing it to compounds that destroy its 
crystal structure. However, hydrogen bonding and hydrophobic interactions are generally necessary to 
maintain the three-dimensional structure of enzymes as well. Thus, chitin-degrading enzymes may be 
inactivated under these strict conditions. Enzyme reactions must be performed under conditions that 
their catalytic activities remain, such as with low concentrations of chemical agents. Recently, some 
novel sodium dodecyl sulfate (SDS)-resistant endochitinases and thermostable chitinases were found in 
the fermentation broth of bacteria [80–82]. These enzymes could be applied to improve the hydrolytic 
efficiency of chitin in the future.  
The most common source of chitin for producing GlcNAc is shellfish biomass. However, the supply 
of  shrimp  and  crab  shells  is  highly  dependent  on  seasonal  and  environmental  factors,  leading  to 
unpredictable limitations on production capacity. Another option to stabilize the chitin source for the 
production of GlcNAc is to utilize a non-shellfish chitin source. In several typical fungal species, at 
least 15% of chitin exists in their cell walls. Chen et al. established a method to produce chitin by 
culturing an Actinomucor taiwanensis fungus. The highest yield of chitin was achieved at 1.5 g/L using 
their fermentation method [83]. The crystal structure of fungal chitin has not yet been characterized, 
although it is hypothesized to be highly susceptible to enzymatic degradation. Mar. Drugs 2010, 8                       
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GlcNAc can be produced using fungal  biomass  as  a substrate. Bohlman  et  al. (2004) obtained 
GlcNAc of high purity by degrading fungal chitin using either acid or enzymes. The concentration of 
GlcNAc obtained by acid degradation was 6.42 mg/mL, while that obtained by enzymatic treatment 
was 4.04 mg/mL [50,84]. Raetz et al. (1998) compared several chitins from different sources and 
tested their susceptibility to enzymes isolated from  Penicillium janthinellum P9. Their results also 
confirm that fungal chitin has a higher susceptibility to hydrolysis than arthropod chitin [85]. 
A continuous production system used to obtain GlcNAc from chitin was described by Louise et al. 
This system involves five essential unit operations: (1) the fermentation unit, which is required for both 
cell  culture  and  the  production  of  chitinolytic  enzymes;  (2)  the  enzyme  recovery  unit;  (3)  the 
pretreatment  of  the  chitin  substrate;  (4)  the  two-stage  chitin-hydrolysis  reactor;  and  (5)  the  final 
purification unit to obtain GlcNAc [86]. 
In the first unit, Serratia marcescens QM B1466 is used to produce chitinolytic enzyme ensembles. 
After induction for four to six days, the chitinase activity in the medium exceeds 105 U/mL, and the 
NAGase activity in the medium is two-fold higher than that of chitinase. In the second unit, chitinolytic 
enzyme ensembles are concentrated using colloidal chitin adsorption or ultrafiltration. In the third unit, 
mechanical methods, such as ball milling and hammer milling, are used to increase the surface area of 
chitin. Physical-chemical methods, such as autoclaving and steam exploding, are then used to swell the 
chitin particles, and treatment with dimethyl acetimide and weak cosolvents are explored to disrupt the 
chitin inter-chain hydrogen bonds.  
In the fourth unit, a novel two-stage chitin-hydrolysis bioreactor was designed to maintain a high 
rate of chitin hydrolysis and GlcNAc production. The configuration of the bioreactor is illustrated in 
Figure  2.  Enzyme  ensembles  are  pumped  into  the  first  reactor,  which  contains  pretreated  chitin 
particles as a packed bed or fluidized bed. Chitinases are adsorbed onto chitin beads, and the beads are 
steadily hydrolyzed. NAGase, which is not adsorbed onto the chitin beads, and the synergetic soluble 
fractions are released into the second stirred reactor. The solid content is recycled back to the first 
reactor.  The  soluble  fractions  are  completely  hydrolyzed  by  NAGase,  making  GlcNAc  the  sugar 
product of the two-stage reactor. The enzyme catalyst stream is continuously recycled into the reactor 
after removing GlcNAc by cross-flow filtration. 
In the fifth unit, a continuous cross-flow ultrafiltration cell is used to separate the GlcNAc product 
from the chitinolytic enzyme ensemble. GlcNAc, with a purity greater than 98%, is recovered in the 
filtrate, and no protein contaminants are detectable. However, the primary oligosaccharide contaminant 
in the product is chitobiose, as detected by HPLC. Further purification procedures are necessary to 
recover GlcNAc from the filtrate. 
This continuous production system is capable of producing GlcNAc at an average productivity of  
78  g/L/h.  The  two-stage  bioreactors  are  operated  continuously  over  a  10-day  period,  reaching  
steady-state production levels after 28 h, and this system is estimated to be an economic process for the 
production of GlcNAc.  
2.4. Production of GlcNAc by biotransformation 
Although economic processes to produce GlcNAc by enzymatic hydrolysis have been established, 
the necessity to arrange so many units is a limiting factor. Efforts to screen indigenous microorganisms Mar. Drugs 2010, 8                       
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from the soil for their ability to degrade chitin have been performed. Li et al. (2005) isolated a microbe, 
which was identified as Aeromonas caviae DYU-BT4, from a soil sample in Taiwan. In a fermentation 
test using chitin particles as a substrate, high chitinase activity (588.6 U/L) was detected, and the 
concentration of reducing sugar in the medium was 0.88 g/L. The major substance in the hydrolysate of 
chitin was GlcNAc. After optimization of the fermentation process, about 7.8 g/L of GlcNAc was 
produced using 2% of colloidal chitin as a substrate. This result indicates that it is possible to produce 
GlcNAc using whole microbes [87]. 
A novel chitin-degrading microbe named Chitinibacter tainanensis was isolated from a soil sample 
that was collected in southern Taiwan and was proven to produce GlcNAc [88]. The GlcNAc yield was 
75% using α-chitin as a substrate and greater than 98% using β-chitin as a substrate. A needle-like 
crystal was produced after the broth was concentrated and crystallized, and the purity of the product 
was  determined  to  be  greater  than 99%. It  is  suggested that some factors, called chitin-degrading 
factors (CDFs), can hydrolyze chitin and are released during the proliferation of C. tainanensis in the 
presence of chitin, with the concomitant production of acidic metabolite. Interestingly, the microbe is 
killed due to the acidic condition of the medium. However, CDFs still hydrolyze chitin, and the final 
product, GlcNAc, accumulates in the medium without being consumed by the microbe because it is 
dead [89]. 
Further studies indicate that CDFs are located on the surface of C. tainanensis. Thus, even if the 
microbes die, CDFs are still docked on the bacterial debris and maintain their chitinolytic activity. To 
determine how CDFs hydrolyze chitin, their endochitinase and NAGase activities have been measured. 
Both of these enzyme activities are found in live bacteria and in dead cell debris. The specific activity 
of NAGase is much higher than that of endochitinase. Therefore, GlcNAc is the only product of this 
biotransformation method. The mechanism of CDFs is similar to that of cellulosome from mesophilic 
bacteria [90] and is illustrated in Figure 3. 
Another  way  to  produce  GlcNAc  is  through  the  genetic  modification  of  microorganisms  using 
glucose as a substrate. Metabolic pathways for GlcN and GlcNAc synthesis can be modified by genetic 
engineering techniques to increase enzyme activities, overexpress proteins, reduce product inhibition 
and increase the affinity of the substrate. A genetically engineered E. coli strain has been developed by 
Den et al. [91] in which GlcN-6-P acetyltransferase, GlcN-6-P synthase and GlcN-1-P acetyltransferase 
are  overexpressed,  while  GlcN-6-P  and  GlcNAc-1-P  uridyltransferase  are  suppressed.  This 
microorganism  contains  additional  genetic  modifications  that  increase  phosphoglucoisomerase, 
glutamine synthetase and glucose 6-P dehydrogenase activities and inactivate phosphofructokinase and 
genes encoding the enzymes responsible for glycogen synthesis to control the flux of metabolites. 
Because glucose is the major substrate for GlcNAc production, fructose is supplemented to maintain 
the energy supply for bacterial proliferation. In this process, a high concentration (exceeding 120 g/L) 
of GlcNAc was obtained after fermentation for 60 h and is, thus, the most efficient process by far. 
3. Applications of GlcNAc 
GlcNAc belongs to a large class of amino sugars that serve a number of functions and are located 
throughout the human system. For example, GlcNAc and its analogues, such as chitin and chitosan, are 
known as the carbon and/or nitrogen sources for creatures. In fact, they also could be used as a biomass. Mar. Drugs 2010, 8                       
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It  has  been  shown  that  Rhodotorula  glutinis  is  able  to  convert  GlcNAc  to  biofuel  [92,93].  The 
bioethanol could be yielded with the GlcNAc from chitin waste as a C6 carbon source [94].  
GlcNAc is also a component of glycoproteins, proteoglycans, GAGs and other connective tissue 
building  blocks  [42].  GAGs  and  glycoproteins  act  as  substrate  materials  for  tissue  repair  and  
anti-inflammatory reactions [95]. When GlcNAc is present in the medium of pig gastric mucosal cells, 
it is  incorporated into high molecular weight  glycoproteins  [96]. Additionally, after 168 h of oral 
administration of GlcNAc, about 25% of GlcNAc accumulates in tested animals [97]. This finding 
indicates that GlcNAc is an important component of biomacromolecular synthesis in the body. 
Certain diseases appear to be related to abnormalities in the formation and utilization of amino 
sugars. Cell membranes, intercellular fluids and cell regeneration could all be affected by GlcNAc. In 
recent years, GlcNAc has been discovered to be a valuable pharmacological agent in the treatment of a 
wide variety of ailments. 
3.1. Safety of GlcNAc 
A large dose of GlcNAc (20 g) given intravenously to human volunteers results in neither toxicity 
nor alteration of blood glucose concentration [42,43]. A lack of insulin resistance was also found after 
oral  administration  of  GlcNAc,  even  at  a  high  dose.  Systematic  toxicological  tests  have  been 
performed in animals, including the acute toxicity test, Ames test, micronucleus test of mouse bone 
marrow cells, abnormality test of mouse sperm, aberration test of mouse testis chromosomes, chronic 
lethal test, sub-chronic toxicity test (for 90 days) and traditional deformity-inducing test [98,99]. These 
experiments indicate that GlcNAc is a valuable compound with high safety in invaded, oral and topical 
usage.  GlcNAc  has  been  widely  utilized  as  a  nutritional  supplement  for  therapeutic  usage.  It  is 
classified as described in the following sections. 
3.2. GlcNAc is used to treat joint damage 
Articular cartilage is a matrix of proteoglycans, chondrocytes and collagens. It absorbs shock from 
mechanical  forces  and  provides  a  smooth  surface  so  that  bone  ends  may  glide  easily  across  one 
another.  Chondrocytes  are  known  to  contribute  to  the  synovial  fluid,  which  bathes  the  articular 
cartilage.  Lack of proteoglycan precursors and synovial fluid  leads  to  defects  in  the structure and 
function of skeletal joints and osteoarthritis occurs. The incidence increases with age and is found in 
most people over the age of 65 [100,101]. 
Many clinical trials have been performed to treat patients with joint disorders, including arthritic 
diseases,  osteoarthritis,  rheumatoid  arthritis,  cartilage  damage,  joint  injury  and  degenerative  joint 
disease (DJD). Preparations containing GlcNAc are delivered by parenteral, oral, transmucosal and 
topical administration. The results from these deliveries indicate that GlcNAc significantly enhances 
the  prevention  of  joint  damage  [102–107].  Moreover,  GlcNAc  also  inhibits  elastase  activity  and 
superoxide release from human polymorphonuclear leukocytes [108,109].  Mar. Drugs 2010, 8                       
 
 
2502 
3.3. GlcNAc is a potential candidate to treat inflammatory bowel disease (IBD) 
Mucous membranes of the entire digestive tract are composed of epithelial cells, which have a high 
rate of turnover. The synthesis of glycoproteins and GAGs by the mucosa is considered to provide 
protection for the lining of bowel. IBD is a generic diagnosis that encompasses a number of bowel 
diseases,  including  ulceracolitis,  chronic  proctitis  and  Crohn’s  disease.  IBD  can  involve  the 
inflammatory disruption of vascular and matrix GAGs, and tumor necrosis factor-α appears to play an 
important role in inflammation [110–112]. The loss of GAGs from the intestinal wall results in fibrosis 
of the bowel. Tissue defects in the digestive tract result in food intolerance, in which food allergens are 
absorbed by the gastrointestinal tract, followed by the development of psoriasis [113,114]. 
GlcNAc  is  capable  of  enhancing  the  release  of  acid  mucopolysaccharides  by  fibroblasts  and 
restoring  the  formation  of  the  protective  structure  of  the  gastrointestinal  tract  [115].  In  addition, 
GlcNAc increases the elasticity of perivascular tissue, resulting in an increase in arterio-capillary blood 
flow. GlcNAc acts as a cytoprotective agent for restoring the integrity and normal function of the 
mucous  membrane  in  humans  [116,117].  A  pilot  clinical  trial  has  been  performed  to  identify the 
therapeutic  effect  of  GlcNAc  on  IBD.  Children  with  symptomatic  Crohn’s  disease  showed  clear 
improvement after either oral or rectal administration of GlcNAc [118]. Therefore, GlcNAc shows 
promise as an inexpensive and non-toxic treatment for chronic IBD. Recently, a phase III clinical trial 
has just been finished [43]. 
3.4. Application of GlcNAc in cosmetics 
Human skin contains stratum corneum and dermis to protect the body from harsh environmental 
conditions, such as dryness and UV irradiation. Stratum corneum plays a key role in maintaining the 
moisture and firmness of the skin. It consists of flattened dead cells, corneocytes and a complex of lipid 
matrix and natural moisture factors [119]. Dermis, the inner layer of the skin, is composed of collagen, 
elastin and GAGs, which are created by fibroblasts. Collagen is responsible for the resilience, strength, 
durability, elasticity, smoothness and plump appearance of healthy skin. Mucopolysaccharides, such as 
HA  and  proteoglycans,  have  a  high  water  retention  capacity  and  are  important  components  in 
maintaining skin moisture. 
When the amount of mucopolysaccharides decreases with age, the water retention and resilience of 
the skin decreases, and thereby causes rough skin and fine wrinkles. Cosmetics, commercially available 
topical preparations have been designed to increase the moisture content of the skin. Most cosmetics 
provide only a short-term replenishment of moisture-providing ingredients. Skin care ingredients that 
are derived from natural substances with high safety ratings are regarded as more beneficial. 
HA, which is produced mainly by fibroblasts and keratinocytes, is a well known ingredient that 
holds water in the stratum corneum and dermis [120]. HA content is reported to decline with age, 
which may contribute to wrinkle formation and the decrease in elasticity of the skin [121]. HA is 
suggested to be a valuable ingredient in cosmetics. However, HA absorb inefficiently by either topical 
or oral administration due to its high molecular weight. Addition of GlcNAc, which is the building unit 
of HA, to cultured keratinocytes results in a dose-dependent increase in the production of HA [122], Mar. Drugs 2010, 8                       
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but has no effect on HA production of skin fibroblasts. Instead, GlcNAc enhances the proliferation and 
collagen expression of fibroblasts [123]. 
Topical administration of GlcNAc is used to improve skin quality. GlcNAc has been shown to be a 
good skin penetrant based on in vitro Franz cell testing. This result is consistent with the joint pain 
relieving effect  of GlcNAc by topical administration [106]. In addition to its moisturizing effects, 
GlcNAc  has  been  found  to  reduce  the  appearance  of  facial  hyperpigmentation  in  an  8-week,  
double-blind  clinical  trial  [124].  Using  in  vitro  genomic  experiments,  the  mechanism  by  which 
GlcNAc reduces melanin production has been found to involve the up-regulation of several genes, such 
as epidermal turnover genes and antioxidant-related genes, and the down-regulation of the cytoskeleton 
genes involved in melanosome transport. These changes are believed to be associated with pigment 
reduction [125]. Due to the versatile functions of GlcNAc, it is considered a valuable ingredient in 
cosmetics  for  improving  skin  wrinkles  and  color  [126,127].  Because  GlcNAc  promotes  the 
proliferation of keratinocytes and fibroblasts and increases the production of HA in the skin, it has also 
been successfully used to heal wounds [128,129]. 
3.5. GlcNAc is used as a substrate in sialic acid production 
N-Acetylneuraminic acid (Neu5Ac) is the most common sialic acid and exists as >40 structural 
derivatives in mammalian and avian species [130]. Sialic acids are found at the distal ends of cell 
surface glycoconjugates and are major determinants of cellular recognition [131], serving as receptors 
for influenza viruses [131–133]. 
Infection of host cells by influenza viruses begins with the binding of hemagglutinin on the virus to 
the end of the sugar chain on the host cell. The infiltrating virus continuously proliferates in the cell. At 
the moment when the virus is to be released from the cell, the neuraminidase located on the surface of 
the virus hydrolyzes the binding site on the superficial layer of the host cell, and the freed virus binds 
to other non-infected cells. Novel pharmaceutical agents that are chemically synthesized from Neu5Ac 
to  produce  neuraminidase  inhibitors  are  used  to  treat  influenza  infections.  Indeed,  Zanamivir,  the 
guanidyl derivative of Neu5Ac, has been approved by several governments as an effective remedy for 
the treatment of the flu [132,133]. 
Because  the  Neu5Ac  content  in  natural  products  is  too  low  for  the  isolation  of  Neu5Ac  with 
sufficient recovery and purity, novel processes had to be developed for the industrial production of this 
compound. Enzymatic synthesis of Neu5Ac from N-acetylmannosamine (ManNAc) and pyruvate using 
Neu5Ac  aldolase  as  a  catalyst  has  been  reported.  However,  because  ManNAc  is  very  expensive, 
methods for the preparation of ManNAc from inexpensive GlcNAc, using chemical epimerization or 
enzymatic conversion by GlcNAc 2-epimerase, have been developed [134]. The simple and large-scale 
production of Neu5Ac using a two-step reaction was performed by Maru et al., in which 29 kg of 
Neu5Ac was obtained from 27 kg of GlcNAc, using recombinant GlcNAc 2-epimerase and Neu5Ac 
lyase  as  catalysts  [135].  Lee  et  al.  (2007)  also  developed  a  method  to  produce  Neu5Ac  using 
recombinant whole cells that express GlcNAc 2-epimerase and recombinant Neu5Ac lyase separately 
[136]. In summary, GlcNAc is an important substrate for the production of sialic acids.  Mar. Drugs 2010, 8                       
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3.6. Other applications of GlcNAc 
A novel GlcNAc application has been developed by Xu et al. Because GlcNAc is a pure compound 
with a high level of safety, it is an appropriate candidate for multiple applications, especially for drug 
development. To test the special functions of GlcNAc, a novel bio-wave model was established with 
the use of Proteus mirabilis. In this model, the swarm colonies of P. mirabilis extend outward, and 
concentric rings are formed on the agar within 3 h as a result of the decay of metabolites [137]. In the 
presence of GlcNAc, many fine waves are formed in each ring, in addition to the typical concentric 
rings. Thus, GlcNAc was shown to portray a finer bio-wave characteristic than other compounds. This 
wave-promoting function may explain the special applications of GlcNAc described in Table 1. A 
series of cytological tests, animal tests and clinical trials have been performed to confirm the special 
functions of GlcNAc. Some of the successful cases have been filed as patents and are being utilized in 
the development of new drugs. 
Table 1. Applications of GlcNAc derived from the bio-wave model 
Function  Object  Trial  Reference 
Disease 
Treatment 
cancer and metastasis  animal, human  [138] 
autoimmune reactions  cell, animal, human  [139] 
urogenital tract infection  cell, human  [140] 
viral or bacterial infection  cell, animal  [141] 
sexual disorder  human  [142] 
non-specific inflammation  animal, human  [143] 
perianal disease  cell, animal, human  [144] 
intestinal disease  human  [145] 
cervical erosion  bacteria, human  [146] 
respiratory tract disease  human  [147] 
Disease 
Prevention 
toxicosis of drugs or 
chemicals 
cell, animal  [148] 
antibiotics  bacteria  [149] 
side effects of radiotherapy 
and chemotherapy 
human  [150] 
cardio-cerebrovascular 
anoxemia 
animal  [151] 
motion sickness  human  [152] 
Dermatology  modulation of 
microorganisms on mucus 
membrane 
animal, human  [153] 
skin sanitary article 
preparation 
human  [154] 
microecological balance of 
mucosa 
bacteria, human  [155] 
Food supplement  additive in milk  animal, human  [156] 
additive in beer  animal, human  [157] 
additive in wine  animal, human  [158] Mar. Drugs 2010, 8                       
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Figure  1.  Production  of  GlcNAc  using  chitin  as  a  substrate.  (1)  Chemical  methods;  
(2)  Enzymatic  methods;  (3)  Improved  enzymatic  methods;  and  (4)  Biotransformation 
methods. 
 
Figure 2. Two-stage chitin-hydrolyss bioreactor.  
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Figure 3. Production of GlcNAc by biotransformation. 
 
 
4. Conclusions 
GlcNAc  is  prepared  using  chitin  as  a  substrate  by  chemical,  enzymatic  and  biotransformation 
methods.  New  methods  using  glucose  as  a substrate can also  be applied to  obtain GlcNAc using 
genetically modified microorganisms. Finally, the versatile functions of GlcNAc promote its use as a 
novel candidate for drug development. 
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